Equities

China NT Pharma Group Co Ltd

China NT Pharma Group Co Ltd

Actions
  • Price (HKD)0.249
  • Today's Change0.011 / 4.62%
  • Shares traded1.26m
  • 1 Year change-62.84%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1.525.939.44
Total Receivables, Net103412
Total Inventory01032
Prepaid expenses------
Other current assets, total0.7124214
Total current assets1273268
Property, plant & equipment, net0.94380248
Goodwill, net000
Intangibles, net0.20159161
Long term investments314278278
Note receivable - long term------
Other long term assets------
Total assets3291,006955
LIABILITIES
Accounts payable0.973845
Accrued expenses10616896
Notes payable/short-term debt000
Current portion long-term debt/capital leases341826618
Other current liabilities, total217138137
Total current liabilities6651,170896
Total long term debt3.600.46214
Total debt345826832
Deferred income tax07757
Minority interest----0
Other liabilities, total----0
Total liabilities6691,2471,167
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital1,8061,7591,759
Retained earnings (accumulated deficit)(2197)(2338)(2272)
Treasury stock - common------
Unrealized gain (loss)0285224
Other equity, total515277
Total equity(340)(242)(211)
Total liabilities & shareholders' equity3291,006955
Total common shares outstanding264190190
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.